Loading
Life sciences · Journal article
Biomedicines · November 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Immuno-metabolic depression (IMD) describes the clustering of atypical energy-related symptoms, low-grade inflammation, and metabolic dysregulation within major depressive disorder. This structured narrative review evaluates its biological basis and potential utility for patient stratification and treatment selection. PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library were searched through July 2026 without a lower publication-date restriction. Clinical, genetic, multi-omics, and neuroimaging evidence links energy-related symptom profiles with inflammatory and metabolic abnormalities. Human observations and preclinical experiments implicate interacting immune, metabolic, endocrine, kynurenine, dopaminergic, and gut–brain pathways, although an IMD-specific causal sequence remains uncertain. C-reactive protein, symptom profiles, and metabolic indices may support research stratification; their ability to predict differential treatment benefit requires validation. Anti-inflammatory and dopaminergic studies report preliminary mechanistic or symptom-related findings in selected samples, while exercise has shown favorable effects on immunometabolic indices. The reviewed semaglutide trial did not demonstrate benefit for the primary executive-function outcome or depressive symptoms, despite favorable secondary findings for global cognition and weight. IMD therefore remains a research framework with potential clinical relevance. Standardized definitions, longitudinal studies, and adequately powered randomized trials are needed to establish whether biomarker-guided treatment selection improves depressive, functional, and cardiometabolic outcomes beyond standard care.